Biotechnology company mAbxience has officially opened the first single-use technology plant in Spain focused on the development of these medicines.
The installations in León will house the development projects forming the group’s pipeline activity and it is expected that, in the future, it will also house production of the biosimilar medicines that will supply the main regulated markets.
Since it began its activity in 2009, the company has invested over 115 million euros ($130.9 million). This represents one of the largest investments by a group of Spanish origin in a biotechnology project.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze